Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE

Elisabetta Valoti1, Marina Noris1, Annalisa Perna1

  • 1Aldo e Cele Daccò Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS, Ranica, Italy.

Frontiers in Genetics
|August 21, 2019
PubMed

Insights

Genetic variants in complement factor H (CFH) are linked to increased risk of kidney and cardiovascular events in type 2 diabetes patients. These CFH variants may reduce the effectiveness of angiotensin-converting enzyme inhibitor (ACEi) therapy.

Area of Science:

  • Nephrology
  • Cardiology
  • Genetics

Background:

  • Complement activation plays a role in type 2 diabetes pathogenesis and complications.
  • Complement factor H (CFH) genetic variants are linked to organ damage via inefficient complement modulation.
  • The impact of specific CFH variants on renal and cardiovascular events in type 2 diabetes, and their interaction with ACEi therapy, remains unclear.

Purpose of the Study:

  • To investigate the association of the c.2808G>T (p.Glu936Asp) CFH polymorphism with renal and cardiovascular events in type 2 diabetes patients.
  • To determine if this CFH polymorphism influences the response to angiotensin-converting enzyme inhibitor (ACEi) therapy.
  • To analyze the risk stratification provided by the p.Glu936Asp polymorphism in the context of microalbuminuria and cardiovascular complications.

Main Methods:

  • Analysis of the p.Glu936Asp CFH polymorphism in 1,158 type 2 diabetes patients from the BENEDICT trial.
  • Prospective follow-up to assess new onset microalbuminuria and cardiovascular events.
  • Multivariable Cox regression analysis to evaluate the association between the polymorphism, ACEi therapy, and clinical outcomes.

Main Results:

  • The Asp/Asp genotype of the p.Glu936Asp CFH polymorphism was associated with a significantly increased risk of microalbuminuria (HR 3.25) and cardiovascular events (HR 2.68).
  • A significant interaction was observed between the p.Glu936Asp genotype and ACEi therapy regarding microalbuminuria prediction.
  • ACEi therapy was not nephroprotective in Asp/Asp homozygotes but was effective in Glu/Asp or Glu/Glu patients. Cardiovascular event risk was higher in ACEi-treated Asp/Asp homozygotes.

Conclusions:

  • Type 2 diabetes patients with the Asp/Asp genotype of the p.Glu936Asp CFH polymorphism face a higher risk of microalbuminuria and cardiovascular complications.
  • These patients may exhibit a diminished benefit from ACEi therapy.
  • Further research is warranted to validate these findings and explore potential therapeutic strategies for this patient subgroup.

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.4K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K
Types of Impact01:30

Types of Impact

Impacts can be classified in various forms, primarily under two subgroups: central impact and oblique impact. A central impact occurs when two objects collide head-on, possessing opposite velocities aligned along the line of impact. Conversely, an oblique impact occurs when two objects collide at an angle, resulting in a modification of both direction and velocity.
The coefficient of restitution is a metric for understanding the dynamics of impacts. It quantifies the ratio of relative velocity...
1.0K
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
433
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
3.9K
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
894